Show simple item record

dc.contributor.authorHtut, Myo
dc.contributor.authorRamanathan, Muthalagu
dc.contributor.authorHari, Parameswaran
dc.date2022-08-11T08:09:49.000
dc.date.accessioned2022-08-23T16:44:57Z
dc.date.available2022-08-23T16:44:57Z
dc.date.issued2018-03-01
dc.date.submitted2018-05-30
dc.identifier.citation<p>Biol Blood Marrow Transplant. 2018 Mar;24(3):478-485. doi: 10.1016/j.bbmt.2017.10.024. Epub 2017 Oct 24. <a href="https://doi.org/10.1016/j.bbmt.2017.10.024">Link to article on publisher's site</a></p>
dc.identifier.issn1083-8791 (Linking)
dc.identifier.doi10.1016/j.bbmt.2017.10.024
dc.identifier.pmid29079457
dc.identifier.urihttp://hdl.handle.net/20.500.14038/40600
dc.description<p>Full author list omitted for brevity. For the full list of authors, see article.</p>
dc.description.abstractWe compared postrelapse overall survival (OS) after autologous/allogeneic (auto/allo) versus tandem autologous (auto/auto) hematopoietic cell transplantation (HCT) in patients with multiple myeloma (MM). Postrelapse survival of patients receiving an auto/auto or auto/allo HCT for MM and prospectively reported to the Center for International Blood and Marrow Transplant Research between 2000 and 2010 were analyzed. Relapse occurred in 404 patients (72.4%) in the auto/auto group and in 178 patients (67.4%) in the auto/allo group after a median follow-up of 8.5 years. Relapse occurred before 6 months after a second HCT in 46% of the auto/allo patients, compared with 26% of the auto/auto patients. The 6-year postrelapse survival was better in the auto/allo group compared with the auto/auto group (44% versus 35%; P = .05). Mortality due to MM was 69% (n = 101) in the auto/allo group and 83% (n = 229) deaths in auto/auto group. In multivariate analysis, both cohorts had a similar risk of death in the first year after relapse (hazard ratio [HR], .72; P = .12); however, for time points beyond 12 months after relapse, overall survival was superior in the auto/allo cohort (HR for death in auto/auto =1.55; P = .005). Other factors associated with superior survival were enrollment in a clinical trial for HCT, male sex, and use of novel agents at induction before HCT. Our findings shown superior survival afterrelapse in auto/allo HCT recipients compared with auto/auto HCT recipients. This likely reflects a better response to salvage therapy, such as immunomodulatory drugs, potentiated by a donor-derived immunologic milieu. Further augmentation of the post-allo-HCT immune system with new immunotherapies, such as monoclonal antibodies, checkpoint inhibitors, and others, merit investigation.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=29079457&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsAuthor's submitted manuscript (preprint) posted as allowed by publisher's article sharing policy at: https://www.elsevier.com/about/our-business/policies/sharing.
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAllogeneic transplantation
dc.subjectMyeloma
dc.subjectRelapse
dc.subjectSurvival
dc.subjectHematology
dc.subjectHemic and Immune Systems
dc.subjectHemic and Lymphatic Diseases
dc.subjectNeoplasms
dc.subjectOncology
dc.titleAutologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival
dc.typePreprint
dc.source.journaltitleBiology of Blood and Marrow Transplantation
dc.source.volume24
dc.source.issue3
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=4415&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/3404
dc.identifier.contextkey12222285
refterms.dateFOA2022-08-23T16:44:58Z
html.description.abstract<p>We compared postrelapse overall survival (OS) after autologous/allogeneic (auto/allo) versus tandem autologous (auto/auto) hematopoietic cell transplantation (HCT) in patients with multiple myeloma (MM). Postrelapse survival of patients receiving an auto/auto or auto/allo HCT for MM and prospectively reported to the Center for International Blood and Marrow Transplant Research between 2000 and 2010 were analyzed. Relapse occurred in 404 patients (72.4%) in the auto/auto group and in 178 patients (67.4%) in the auto/allo group after a median follow-up of 8.5 years. Relapse occurred before 6 months after a second HCT in 46% of the auto/allo patients, compared with 26% of the auto/auto patients. The 6-year postrelapse survival was better in the auto/allo group compared with the auto/auto group (44% versus 35%; P = .05). Mortality due to MM was 69% (n = 101) in the auto/allo group and 83% (n = 229) deaths in auto/auto group. In multivariate analysis, both cohorts had a similar risk of death in the first year after relapse (hazard ratio [HR], .72; P = .12); however, for time points beyond 12 months after relapse, overall survival was superior in the auto/allo cohort (HR for death in auto/auto =1.55; P = .005). Other factors associated with superior survival were enrollment in a clinical trial for HCT, male sex, and use of novel agents at induction before HCT. Our findings shown superior survival afterrelapse in auto/allo HCT recipients compared with auto/auto HCT recipients. This likely reflects a better response to salvage therapy, such as immunomodulatory drugs, potentiated by a donor-derived immunologic milieu. Further augmentation of the post-allo-HCT immune system with new immunotherapies, such as monoclonal antibodies, checkpoint inhibitors, and others, merit investigation.</p>
dc.identifier.submissionpathoapubs/3404
dc.contributor.departmentDivision of Hematology and Oncology, Department of Medicine
dc.source.pages478-485


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
4aperto_1_s2.0_S10838791173079 ...
Size:
614.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Author's submitted manuscript (preprint) posted as allowed by publisher's article sharing policy at: https://www.elsevier.com/about/our-business/policies/sharing.
Except where otherwise noted, this item's license is described as Author's submitted manuscript (preprint) posted as allowed by publisher's article sharing policy at: https://www.elsevier.com/about/our-business/policies/sharing.